洞察市场格局
解锁药品研发情报

400客服电话

  • 购买数据产品

    400-9696-311 转1

  • 定制咨询业务

    400-9696-311 转2

  • 数据与AI定制业务

    400-9696-311 转3

  • 商务合作及其他问题

    400-9696-311 转4

  • 投诉及建议

    400-9696-311 转5

医药数据查询

【ChiCTR2600132371】Building Resilience Against Rising Temperature - The Effect of High-Intensity Interval Exercise (HIIE) on Heat Tolerance, Thermoregulatory Adaptation, and Physical Fitness: A Comparative Randomized Controlled Trial

基本信息
登记号

ChiCTR2600132371

试验状态

尚未开始

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2026-09-14

临床申请受理号

/

靶点

/

适应症

NA

试验通俗题目

Building Resilience Against Rising Temperature - The Effect of High-Intensity Interval Exercise (HIIE) on Heat Tolerance, Thermoregulatory Adaptation, and Physical Fitness: A Comparative Randomized Controlled Trial

试验专业题目

Building Resilience Against Rising Temperature - The Effect of High-Intensity Interval Exercise (HIIE) on Heat Tolerance, Thermoregulatory Adaptation, and Physical Fitness: A Comparative Randomized Controlled Trial

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

联系人通讯地址
请登录查看
临床试验信息
试验目的

1.To evaluate whether high-intensity interval training performed under thermoneutral environmental conditions improves physiological resilience to heat stress 2.To determine whether high-intensity interval training is the most effective exercise intervention to enhance heat resilience and thermoregulatory capacity compared with other traditional exercise types

试验分类
请登录查看
试验类型

随机平行对照

试验分期

其它

随机化

Selected participants will then be randomly assigned to one of the four groups using a computer-generated randomization schedule. This process will ensure that the groups are comparable at baseline regarding age, gender, and fitness levels. Randomization will be conducted by an independent researcher who will not be involved in the intervention.

盲法

A blinded data analyst who is not involved in participant recruitment, intervention delivery, or outcome assessment will conduct the statistical analyses. Participants will be identified only by unique study codes, and no personally identifiable information will be provided to the analyst. Intervention allocation will be masked using coded group labels (e.g., Group A, B, C, and D), such that the analyst will not know which code corresponds to the HIIE, MICE, WALK, or control group during data cleaning and primary statistical analysis. The group allocation code will be revealed only after the primary analyses have been completed and finalized.

试验项目经费来源

General Research Fund (GRF)

试验范围

/

目标入组人数

25

实际入组人数

/

第一例入组时间

2026-09-23

试验终止时间

2027-09-23

是否属于一致性

/

入选标准

1. Ethnic Chinese adults aged 18–40 years. 2. Physically inactive, defined as engaging in less than 150 minutes of moderate-intensity physical activity per week. 3. Normal body weight (BMI <24 kg/m^2). 4. Free from chronic illnesses that would contraindicate exercise participation, such as cardiovascular diseases (including uncontrolled hypertension), metabolic disorders, or musculoskeletal injuries. 1. Ethnic Chinese adults aged 18–40 years. 2. Physically inactive, defined as engaging in less than 150 minutes of moderate-intensity physical activity per week. 3. Normal body weight (BMI <24 kg/m^2). 4. Free from chronic illnesses that would contraindicate exercise participation, such as cardiovascular diseases (including uncontrolled hypertension), metabolic disorders, or musculoskeletal injuries.;

排除标准

1. Individuals with a history of heat-related illness, recent surgery, or any medical condition that may impair their ability to safely participate in exercise. 2. Pregnant women and individuals currently taking medications that may affect thermoregulation or cardiovascular responses (e.g., beta-blockers, anticholinergic agents, stimulants, or other relevant medications). 3. Individuals with regular occupational or habitual heat exposure that may induce heat acclimation or acclimatization (e.g., outdoor workers or individuals who regularly use saunas).;

研究者信息
研究负责人姓名
请登录查看
试验机构

The Chinese University of Hong Kong

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

/

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

The Chinese University of Hong Kong的其他临床试验

The Chinese University of Hong Kong的其他临床试验

最新临床资讯

摩熵医药企业版
50亿+条医药数据随时查
7天免费试用

全球药物研发中心
全球研发数据与行业前沿情报

388,096个
全球在研药物数
3,065个
本月临床试验数
全球批准的新药
更多
全球首批
各国首批
数据来源:摩熵医药
更新时间:
研发动态
相关报告
政策法规
更多信息,请进入全球药物研发中心查看

医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测

2,632亿元
2026年Q2总销售额
6.14%(2026Q2)
TOP5企业市场份额
药品销售排行榜
查看完整数据
2025Q4医院化学药销售增速 *按市场份额排序
  • 1
    甲氨蝶呤注射液
  • 2
    克霉唑阴道乳膏
  • 3
    氯化钠注射液
核心能力
  • 医药市场销售数据分析 · 医院、实体药店、网上药店
  • 市场竞争格局分析(靶点、药品类型、ATC大类)
更多信息,请进入医药市场洞察中心查看